DDS Diagnostic

What DDS Diagnostic does

DDS Diagnostic is a privately held Romanian diagnostic test developer headquartered in Bucharest, founded in 2002. The company focuses on rapid diagnostic tests, with its most prominent product being the first rapid SARS-CoV-2 antigen test brought to market. The firm operates at a small scale, with 11–50 employees according to available firmographic data.

The company's core technology and product portfolio center on rapid immunoassay-based diagnostic tests for infectious disease detection, although specific technical details, assay platforms, and product specifications are not disclosed in the available source material. The SARS-CoV-2 antigen test, developed during the COVID-19 pandemic, represents the company's flagship commercial product and its primary entry into mainstream public health diagnostics.

The business model appears to be B2B distribution of diagnostic test kits to healthcare providers, laboratories, and potentially public health agencies, consistent with industry norms for IVD manufacturers. However, no pricing model, distribution channels, customer segments, revenue figures, or partnership agreements are disclosed in the available data. The company's website does not currently load substantive content, limiting due diligence.

Name

DDS Diagnostic

Website

https://ddsdiagnostic.com

Company type

Private

Founded year

2002

Headcount range

11–50 employees

Short description

DDS Diagnostic is a Bucharest-based developer of rapid diagnostic tests founded in 2002, best known for producing the first rapid SARS-CoV-2 antigen test. The privately held firm serves the infectious disease diagnostics market with a small team of 11–50 employees.

Ownership category

akta.pro rank

Product category

Rapid In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category) (HLAHAOAH)

akta.pro secondary industry

Point-of-Care (POC) & Rapid Diagnostics (near-patient, lateral flow) (HLAAALAG)

Keywords

• Rapid diagnostic tests
• Antigen test kits
• In vitro diagnostics
• Infectious disease testing
• Point-of-care diagnostics

Headquarters

HQ city

Bucharest

HQ country

Romania

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations

Core offering

DDS Diagnostic develops rapid diagnostic tests, including the first rapid SARS-CoV-2 antigen test. The company manufactures in vitro diagnostic kits used by clinical laboratories and healthcare providers to detect infectious diseases at the point of care.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Direct peers

• ACON Laboratories: Developer of the Flowflex COVID-19 rapid antigen test and a broad portfolio of lateral flow diagnostics. A direct lateral flow test developer and OEM manufacturer with overlapping customer segments.
• Access Bio: Manufacturer of the CareStart COVID-19 rapid antigen test and other lateral flow assays. A direct peer as a focused rapid diagnostics developer with overlapping infectious disease product lines.
• SD Biosensor: Korean IVD company specializing in rapid antigen and antibody tests including STANDARD Q COVID-19 Ag. Directly comparable as a rapid diagnostic test manufacturer serving global public health tenders.
• QuidelOrtho: Specialist in rapid point-of-care diagnostics including the Sofia SARS Antigen FIA. Directly comparable to DDS Diagnostic in lateral flow and rapid immunoassay product focus.

Broad incumbents

• Siemens Healthineers: Major diagnostics and medical device company offering a portfolio that includes rapid testing solutions. Comparable as a broad incumbent in the in vitro diagnostics space.
• Abbott Rapid Diagnostics: Global diagnostics leader whose BinaxNOW COVID-19 antigen test defined the rapid lateral flow category. Comparable to DDS Diagnostic as a developer and manufacturer of rapid antigen tests for infectious disease.
• Becton Dickinson (BD) Veritor: Major medical device company whose BD Veritor system delivers rapid antigen testing at point of care. Comparable in rapid diagnostic platform development and global market reach.
• Roche Diagnostics: Global IVD leader with rapid antigen and molecular diagnostic offerings. Comparable to DDS Diagnostic as a broad diagnostic substance and test developer, with much larger scale and distribution.

Emerging players

• LumiraDx: Point-of-care diagnostics developer with a microfluidic rapid antigen platform. Comparable as a smaller, focused rapid diagnostics company pursuing broader respiratory and infectious disease menus.
• Mologic (now Global Access Diagnostics): Developer of lateral flow rapid tests including COVID-19 antigens. A comparable niche rapid test developer focused on infectious disease diagnostics, with emphasis on low- and middle-income markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xx.com/ddsdiagnostic
• Facebookfacebook.com/ddsdiagnostic
• LinkedInlinkedin.com/company/ddsdiagnostic

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DDS Diagnostic